Crown Prince Mohammed bin Salman of Saudi Arabia has revealed a new strategy to localize vaccine manufacturing and enhance the country’s healthcare sector.

According to the Saudi Press Agency, the National Biotechnology Strategy in Saudi Arabia also aims to safeguard the environment and contribute to achieving water security.

“Localization and biomanufacturing play a vital role in driving the strategy forward, as Saudi Arabia aims to establish itself as the primary biotechnology hub in the MENA region,” said the SPA report. 

“Developing advanced biopharma manufacturing capabilities and establishing a cutting-edge local end-to-end biomanufacturing platform are crucial steps,” it added. 

The strategy places significant emphasis on doubling the country’s self-sufficiency in ensuring timely access to medicines for its citizens. It also aims for a 3% contribution of the biotechnology sector to the non-oil GDP by 2040, with an anticipated impact of $34.66 billion. Additionally, the strategy is expected to generate more job opportunities.

The strategy focuses on four strategic aims, including vaccines, strongly emphasizing localizing vaccine production, exporting, and leading innovation in the field. The program prioritizes local biomanufacturing. Additionally, the strategy outlines genomics, focusing on pioneering research, gene therapy, and plant enhancement.

Now accepting applications for Fast Company Middle East’s Best Workplaces For Women 2023. Click here to register.